Heather Wynn, Pharm.D.

Assistant Professor
612-624-9156
wynnx004@umn.edu

Educational Background

• University of Pittsburgh, Pittsburgh, PA (1997), B.S. (Pharmacy)
• University at Buffalo, Buffalo, NY (1999), Pharm.D.
• Erie County Medical Center/University at Buffalo, Buffalo, NY (2000), Residency (HIV/ID)
• University of Minnesota, Minneapolis, MN (2002), Fellowship (Clinical Pharmacology)

Professional Background

• Community Pharmacy Intern, Jiunta's Pharmacy, Wilkes-Barre, PA, 1994 – 1994
• Hospital Pharmacy Intern, Allegheny General Hospital, Pittsburgh, PA, Pharmacy, 1995 – 1997
• Clinical Skills Laboratory Teaching Assistant, University at Buffalo, Buffalo, NY, Pharmacy Practice, 1997 – 1997
• Clinical Instructor, University at Buffalo, Buffalo, NY, Pharmacy Practice, 1999 – 2000
• Contributing Editor: HIV Pharmacotherapy Website, University at Buffalo, Buffalo, NY, Pharmacy Practice, 1999 – 2000
• Teaching Assistant, Applied Pharmacokinetics, University of Minnesota, Minneapolis, MN, Experimental & Clinical Pharmacology, 2002 – 2002
• Outpatient Pharmacist, VA Medical Center, Minneapolis, MN, 2000 – 2003
• Assistant Professor, University of Minnesota, Minneapolis, MN, Laboratory Medicine and Pathology/Experimental and Clinical Pharmacology, 2002 - present

Professional Honors

• Ortho-McNeil Infectious Diseases Research Fellowship, American College of Clinical Pharmacy, 2001 – 2002
• Clinical Research Feasibility Funds (CReFF) Award , University of Minnesota General Clinical Research Center, 2003 - 2005

Professional Memberships

• American Pharmaceutical Association, 1996 – 1999
• American Society of Health System Pharmacists, 1998 – 1999
• New York State Chapter of the American College of Clinical Pharmacy, 1999 – 2000
• Lambda Kappa Sigma Pharmaceutical Fraternity for Women, 1993 – present
• American College of Clinical Pharmacy, 1999 – present
• Society of Infectious Diseases Pharmacists, 2000 – present
• Minnesota Adult AIDS Clinical Unit Core Committee, 2002 – present
• Adult AIDS Clinical Trials Group Pharmacology Committee, 2003 – present
• Drug Interaction Working Group of the Adult AIDS Clinical Trials Group Pharmacology Committee, 2003 - present
  

Research Interests

Antiviral clinical pharmacology with a specific interest in antiretroviral agents.

Publications

• Esch, L., Hardy, H., Wynn, H.E., Shelton, M.J., Hewitt, R.G., and Morse, G.D., Pharmacist-coordinated adherence enhancement program improves virologic response to highly active antiretroviral therapy, Annual Meeting of the American College of Clinical Pharmacy, Kansas City, MO. October 24 - 27, 1999
• Esch, L., Hardy, H., Wynn, H.E., and Shelton, M.J., Discrepancy between patient-reported adherence and pharmacist-assessed adherence to antiretroviral therapy in patients with human immunodeficiency virus infection, Annual Meeting of the American College of Clinical Pharmacy, Los Angeles, CA. November 5 - 8, 2000
• Shelton, M.J., Wynn, H.E., Hewitt, R.G., and Difrancesco, R., Effects of grapefruit jutce on pharmacokinetic exposure to indinavir in HIV-positive subjects, J Clin Pharmacol, 41:435-442, 2001
• Shelton, M.J., Wynn, H.E., Scott, J., and Hewitt, R.G., Risk of amprenavir rash in HIV patients with prior exposure to sulfonamides, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. December 16 - 19, 2001
• Raynor, C., Esch, L., Wynn, H.E., and Eales, R., Symptomatic hyperbilirubinemia after the addition of ritonavir to an indinavir-containing regimen, Pharmacotherapy, 35:1391-1395, 2001
• Esch, L., Hardy, H., Wynn, H.E., Shelton, M.J., Hewitt, R.G., and Morse, G.D., Intensive adherence interventions improve virologic response to antiretroviral therapy (ART) in naive patients, 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 4 - 8, 2001
• Fletcher, C.V., Anderson, P.L., Kakuda, T.N., Hellman, N., Wynn, H.E., and Brundage, R.C., Anovel approach to integrate pharmacologic and virologic characteristics: an in vivo potency (IVP) index for antiretroviral therapy, 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 4 - 8, 2001
• Wynn, H.E., Anderson, P.L., and Fletcher, C.V., Pharmacokinetic characteristics of protease inhibitor-based salvage antiretroviral treatment regimens, Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM. October 20 - 23, 2002
• Wynn, H.E., Brundage, R.C., and Fletcher, C.V., Clinical implications of CNS penetration of antiretrovirals, CNS Drugs, 16(9):595-609, 2002
• Wynn Vezina, H.E., Brundage, R.C., Bushman, L., and Fletcher, C.V., Pharmacologic management of the drug-drug interaction between lopinavir/ritonavir (LPV/r) and amprenavir (APV), 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. February 8 - 11, 2004
• Hermsen E.D., Wynn H.E., and McNabb J., Discontinuation of prophylaxis for HIV-associated opportunistic infections in the era of highly active antiretroviral therapy, Am J Health Syst Pharm, 61(3):245-56, 2004
• King, J.R., Wynn, H.E., Brundage, R.C., and Acosta, E.P. Pharmacokinetic enhancement of protease inhibitor therapy, Clin Pharmacokinet, 43(5):291-310, 2004
• Wynn Vezina, H.E., Henry, K., Ravindran, G.D., Kurpad, A.V., Raj, T.D.S., Fox, K., Weller, D., Brundage, R.C., Bromander, R., Cavert, W., and Balfour Jr., H.H., International bioequivalence study of generic and brand formulations of nevirapine, zidovudine and lamivudine, 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. February 22 - 25, 2005